LFCR (Lifecore Biomedical) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LFCR Lifecore Biomedical Inc LFCR
59 GF Score
Price $4.48
GF Value $5.79
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Lifecore Biomedical Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Lifecore Biomedical  (NAS:LFCR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Lifecore Biomedical Cyclically Adjusted PB Ratio Related Terms


Lifecore Biomedical Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Lifecore Biomedical's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Cyclically Adjusted PB Ratio Chart

Lifecore Biomedical Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.40 1.08 0.99 0.77 1.02

Lifecore Biomedical Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.79 0.94 0.55 0.76

LFCR vs ADCT, DERM, BGM: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lifecore Biomedical Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's Cyclically Adjusted PB Ratio falls into.


LFCR
59GF Score
Lifecore Biomedical Inc LFCR
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lifecore Biomedical Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Lifecore Biomedical's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Lifecore Biomedical's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.904/333.9520*333.9520
=-0.904

Current CPI (Jun. 2026) = 333.9520.

Lifecore Biomedical Quarterly Data

Book Value per Share CPI Adj_Book
201602 7.632 237.111 10.749
201605 7.822 240.229 10.874
201608 7.964 240.849 11.043
201611 8.054 241.353 11.144
201702 8.209 243.603 11.254
201705 8.297 244.733 11.322
201708 8.404 245.519 11.431
201711 8.452 246.669 11.443
201802 9.078 248.991 12.176
201805 9.117 251.588 12.102
201808 9.131 252.146 12.093
201811 9.126 252.038 12.092
201902 9.311 252.776 12.301
201905 9.282 256.092 12.104
201908 9.090 256.558 11.832
201911 8.884 257.208 11.535
202002 8.487 258.678 10.957
202005 7.939 256.394 10.341
202008 7.563 259.918 9.717
202011 7.125 260.229 9.144
202102 6.978 263.014 8.860
202105 6.913 269.195 8.576
202108 6.580 273.567 8.032
202111 5.298 277.948 6.365
202202 4.887 283.716 5.752
202205 2.976 292.296 3.400
202208 2.716 296.171 3.062
202211 2.448 297.711 2.746
202302 1.128 300.840 1.252
202305 -0.140 304.127 -0.154
202308 -0.445 307.026 -0.484
202311 0.047 307.051 0.051
202402 0.579 310.326 0.623
202405 0.370 314.069 0.393
202408 -0.127 314.796 -0.135
202411 0.418 315.493 0.442
202502 0.060 319.082 0.063
202505 0.036 321.465 0.037
202603 -0.759 330.213 -0.768
202606 -0.904 333.952 -0.904

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Lifecore Biomedical (LFCR) Overvalued in 2026?

Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued. The current stock price of $4.48 is trading 22.7% below its estimated GF Value™ of $5.79. GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.

Key valuation signals for LFCR:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $5.79 vs. price of $4.48 (22.7% below fair value)
  • GF Score™: 59/100 with 3 warning signs

No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lifecore Biomedical Business Description

Other Exchanges LDE:Germany
Address 3515 Lyman Boulevard, Chaska, MN, USA, 55318
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
59GF Score

Get the complete analysis for LFCR

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.48
Price
$5.79
GF Value